Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
Urothelial carcinoma (UC) is a common malignancy of the lower and upper urinary tract. Recurrent UC has poor prognosis due to delayed diagnosis and a lack of clinical management guidance, especially for upper urinary tract UC. Patients with germline or somatic BRCA1/2 mutations are a special populat...
Main Authors: | Hong Yang, Zhimin Liu, Yufang Wang, Jun Li, Ruiqian Li, Qilin Wang, Chen Hu, Haiyang Jiang, Hongyi Wu, Lele Song, Yu Bai |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920970845 |
Similar Items
-
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
by: Kayo Inoue, et al.
Published: (2020-05-01) -
Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021-04-01) -
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01) -
Lynparza (olaparib)
by: Erik Škof, et al.
Published: (2016-06-01) -
Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)